BridgeMD
Prevention study for Cancer Patients Undergoning Radiotherapy
Official title Pinoxin for the Prevention of Radiation-Induced Skin Injury
ClinicalTrials.gov ID: NCT07545720
What this study is testing
What is pinoxin?
pinoxin is an investigational medicine, given as an once-daily, being studied as a potential treatment for cancer patients undergoning radiotherapy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The incidence of radiation-induced skin injury is high, and effective preventive measures are currently lacking. This study evaluates the role of the skin protective agent Pinoxin in preventing skin injury.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years, regardless of gender.
- Pathologically diagnosed with a malignant tumor.
- Scheduled to receive long-course radiotherapy with a total dose of ≥50 Gy, in accordance with standard treatment guidelines.
- No prior history of radiotherapy.
- Has provided signed and dated informed consent, indicating that the patient has been informed of all relevant aspects of the study.
You likely can't join if
- History of dermatologic conditions (e.g., vitiligo, psoriasis, etc.) or collagen vascular diseases.
- Planned hypofractionated radiotherapy regimen.
- Recent use (e.g., within 3 months) of similar topical protective agents.
- Known hypersensitivity to any related components or materials.
- Immunodeficiency disorders.
- Women who are pregnant or lactating.
See the full eligibility criteria
- Age ≥ 18 years, regardless of gender.
- Pathologically diagnosed with a malignant tumor.
- Scheduled to receive long-course radiotherapy with a total dose of ≥50 Gy, in accordance with standard treatment guidelines.
- No prior history of radiotherapy.
- Has provided signed and dated informed consent, indicating that the patient has been informed of all relevant aspects of the study.
- Patients who are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- History of dermatologic conditions (e.g., vitiligo, psoriasis, etc.) or collagen vascular diseases.
- Planned hypofractionated radiotherapy regimen.
- Recent use (e.g., within 3 months) of similar topical protective agents.
- Known hypersensitivity to any related components or materials.
- Immunodeficiency disorders.
- Women who are pregnant or lactating.
- Any other condition that, in the investigator's judgment, may compromise patient safety or protocol compliance. This includes severe concomitant illnesses (including psychiatric disorders) requiring active treatment...
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China; Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.